Navigation Links
ChemoCentryx Announces 2011 Fourth Quarter and Full Year Financial Results
Date:3/30/2012

8 and the ChemR23 research program in 2011.

Research and development expenses for the fourth quarter 2011 were $5.4 million compared to $8.1 million for the same period in 2010. Research and development expenses for the year ended December 31, 2011 were $28.4 million compared to $33.5 million in 2010. The decrease was primarily due to the completion of the Phase II clinical trial for CCX354 in 2011.

General and administrative expenses for the fourth quarter of 2011 were $1.9 million and the same for the comparable period in 2010. General and administrative expenses for the year ended December 31, 2011 were $7.6 million compared to $7.3 million for 2010.

Cash, cash equivalents and investments totaled $96.1 million at December 31, 2011, compared to $82.8 million at December 31, 2010.

2012 Financial OutlookProjected 2012 year-end cash, cash equivalents and investments is expected to be at least $115.0 million.

About ChemoCentryxChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.  Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282, GSK1605786 or GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
(Date:8/30/2014)... Recently, Top 10 Best SEO Hosting (Top10BestSEOHosting.com) has ... BlueHost and JustHost ( http://www.justhost.com/track/seohosts ) are great ... high quality web hosting. , “The hosting ... companies who outperform their competitors on hosting features, ... spokesman for Top 10 Best SEO Hosting says, ...
(Date:8/30/2014)... August 31, 2014 Recently, iFitDress.com, one ... its new designs of classy bridesmaid dresses . ... discounts (from 22 percent off to 62 percent off) ... extremely beautiful items. , True enough, iFitDress.com is ... special occasion gowns. The company persists in making trendy ...
(Date:8/30/2014)... Fast hosting is a great ... recently compared many professional web hosting suppliers and ... Arvixe are the suppliers of fastest web hosting ... a good fast hosting supplier. Actually, these companies ... server speed and customer support. People can get ...
(Date:8/30/2014)... Recently, Skmen.com, a well-known clothing manufacturer, has ... . Before the middle of September, all the company’s ... from 15 to 30 percent off. , As ... outfits are carefully made and come with quality guarantees. ... wearers. Skmen.com is popular for its fashionable, high quality ...
(Date:8/30/2014)... Information supplied by insurance companies has been helping ... consumers in 2014. A group of ratess for term ... open system for adults at http://quotespros.com/life-insurance.html . ... year can help the average person to quote a ... from medical histories. The finder tool works under a ...
Breaking Medicine News(10 mins):Health News:Great Web Hosting Suppliers Recently Recommended by Top10BestSEOHosting.com 2Health News:Classy Bridesmaid Dresses Announced By Loved Online Supplier iFitDress.com 2Health News:Fastest Web Hosting Suppliers In 2014 Announced By Top10BestSEOHosting.com 2Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2
... 8 OECD,s latest survey of the United States, to ... the challenges facing the new administration amid a severe economic ... healthcare. The Washington D.C. launch will be held on Capitol ... and will offer first a panel discussion to present the ...
... Join the Faces of Influenza Campaign to Promote Annual Vaccination ... Supports National Influenza Vaccination Week (December 8-14); Urges Immunization Throughout ... KANSAS CITY, MO., Dec. 8 Health experts ... the U.S. Despite this recommendation, influenza immunization rates fall far ...
... Study estimates US treatment costs at $4 billion, similar ... Each year in the United States, treatment of childhood ... for asthma and attention-deficit hyperactivity disorder (ADHD), according to ... Columbus, Ohio. , They analyzed 2003-04 data on children ...
... New York State Health Foundation, Ford Foundation, New York City Investment ... Robert Wood Johnson Foundation Among Investors to Join Leading Advocate for ... for One-Third of America’s Workforce , ... NEW ...
... Dec. 8 Aurora Health Care and Associated Surgical ... surgery centers, announced today that they have entered into ... the surgery center in Franklin. , ... innovative provider organizations that will work in partnership to ...
... from cell death and exerts resistance to chemotherapy has an ... and kill the very tumor cells it usually protects, researchers ... new study published in the Dec. 9 issue of ... called a kinase, that is hyperactive in the majority of ...
Cached Medicine News:Health News:OECD Economic Survey of the United States 2Health News:The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:Childhood Constipation Carries a Big Price Tag 2Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 2Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 3Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 4Health News: Prominent Philanthropies and Businesses Join Freelancers Union to Pioneer New Health Insurance Model 5Health News:Aurora and Associated Surgical & Medical Specialists Announce Surgery Center Joint Venture 2Health News:An Achilles heel in cancer cells 2
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Delicate # 4...
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model....
Medicine Products: